** Shares of gene therapy developer Rocket Pharmaceuticals RCKT.O rise 1.8% to $3.42 premarket
** Company says it is reducing headcount by about 30% and its 12-month cash burn by nearly 25%
** Adds it is restructuring its drug development program to focus on its cardiovascular therapies and its main gene therapy candidate, kresladi, being developed for the treatment of a rare immunodeficiency disorder called severe leukocyte adhesion deficiency
** Up to last close, stock down 73.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。